ADC Therapeutics Q4 Adjusted EPS $(0.97) May Not Be Comparable To $(0.50) Estimate, Sales $16.79M Beat $15.33M Estimate
Portfolio Pulse from Benzinga Newsdesk
ADC Therapeutics (NYSE:ADCT) reported a Q4 adjusted EPS of $(0.97), missing the consensus estimate of $(0.50) by 94%. Year-over-year, this represents a 1112.5% decrease in EPS. However, Q4 sales of $16.79M exceeded expectations by 9.52%, despite being 75.94% lower than the same period last year.

March 13, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ADC Therapeutics reported a significant miss in Q4 EPS but exceeded sales estimates. The EPS was $(0.97), missing the $(0.50) estimate, and sales were $16.79M, beating the $15.33M estimate.
The significant miss in EPS is likely to negatively impact investor sentiment in the short term, overshadowing the sales beat. The drastic year-over-year decrease in both EPS and sales further compounds concerns about the company's financial health and growth trajectory.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100